Marathon Trading Investment Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-20,000
Closed -$510K 393
2025
Q3
$510K Sell
20,000
-20,200
-50% -$499K 0.04% 154
2025
Q2
$974K Buy
40,200
+37,800
+1,575% +$882K 0.12% 100
2025
Q1
$60.8K Buy
2,400
+800
+50% +$20.9K 0.01% 292
2024
Q4
$42.4K Sell
1,600
-33,600
-95% -$911K ﹤0.01% 269
2024
Q3
$1.02M Buy
35,200
+35,100
+35,100% +$1.02M 0.09% 94
2024
Q2
$2.8K Buy
+100
New +$2.75K ﹤0.01% 280
2023
Q4
Sell
-35,000
Closed -$1.16M 396
2023
Q3
$1.16M Buy
35,000
+24,900
+247% +$881K 0.1% 96
2023
Q2
$370K Sell
10,100
-13,400
-57% -$522K 0.03% 140
2023
Q1
$959K Buy
+23,500
New +$1.01M 0.07% 105
2022
Q4
Sell
-6,800
Closed -$298K 315
2022
Q3
$298K Sell
6,800
-2,900
-30% -$141K 0.03% 191
2022
Q2
$509K Sell
9,700
-36,700
-79% -$1.87M 0.06% 154
2022
Q1
$2.4M Buy
+46,400
New +$2.41M 0.21% 76
2021
Q1
Sell
-18,500
Closed -$681K 479
2020
Q4
$681K Buy
+18,500
New +$679K 0.04% 195
2013
Q3
Sell
-62,186
Closed -$1.65M 171
2013
Q2
$1.65M Buy
+62,186
New +$1.72M 0.11% 56

Other funds holding PFE

Marathon Trading Investment Management's PFE Position: Q3 2025 in Review

Marathon Trading Investment Management sold out of Pfizer (PFE) in Q3 2025, closing a stake of 17,880 shares — an estimated $441K sold.

Marathon Trading Investment Management first reported a position in PFE in Q2 2013 and held it in 19 quarters. The position peaked at $4.8M in Q4 2023. 2,812 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

  • Marathon Trading Investment Management reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
  • Marathon Trading Investment Management sold 17,880 Pfizer shares in Q3 2025, an estimated $441K.
  • Marathon Trading Investment Management first reported a position in Pfizer in Q2 2013 and held it in 19 quarters.
  • Marathon Trading Investment Management's Pfizer position peaked at $4.8M in Q4 2023.
  • 2,812 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on Marathon Trading Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.